SAGE Therapeutics Inc. (NASDAQ:SAGE) Hits New Highs on positive top-line data in exploratory trial of SAGE-547 in Postpartum Depression Print E-mail
By Josh Gee   
Tuesday, 09 June 2015 15:12
SAGE Therapeutics Inc. (NASDAQ:SAGE) has brought out the top-line data from exploratory clinical trial which shows that a big improvement in depression from a baseline level in four women with postpartum depression (PPD) in less than 24 hours through SAGE-547.
Read more...
 
Horizon Pharma PLC starts Phase 3 Trial of ACTIMMUNE for treating People With Friedreich's Ataxia Print E-mail
By Marilyn Mullen   
Monday, 08 June 2015 14:14
Biopharmaceutical firm Horizon Pharma PLC. (NASDAQ:HZNP) has started Phase 3 Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia study for treating people with a degenerative neuro-muscular disorder, Friedreich's Ataxia.
Read more...
 
AbbVie's Ibrutinib improves survival for treatment chronic lymphocytic Leukemia Patients in Phase III RESONATE-2 Trial Print E-mail
By Josh Gee   
Thursday, 04 June 2015 18:57
Pharmacyclics LLC, an AbbVie Inc. (NYSE:ABBV), has confirmed that ibrutinib improved progression-free survival and multiple secondary endpoints which includes overall survival and overall response rate  in treating patients suffering from chronic lymphocytic leukemia.
Read more...
 
Synthetic Biologics Comes With Initial Data Validating Platform Expansion Print E-mail
By Marilyn Mullen   
Wednesday, 03 June 2015 18:36
Synthetic Biologics Inc. (NYSEMKT:SYN) came out with the initial data supporting the firm’s development of a platform of therapeutics made for protecting microbiome from carbapenems, a series of beta-lactam antibiotics.
Read more...
 
Insys Therapeutics Inc (NASDAQ:INSY) Submits NDA for Dronabinol Oral Solution Print E-mail
By Josh Gee   
Wednesday, 03 June 2015 07:41
Insys Therapeutics Inc (NASDAQ:INSY) has confirmed submission of a New Drug Application to U.S. Food and Drug Administration (FDA) for the proprietary Dronabinol Oral Solution for weight loss in patients with AIDS along with vomiting associated with cancer chemotherapy in some patients having failed to respond appropriately to usual antiemetic treatments. 
Read more...
 
Heron Therapeutics Inc(NASDAQ:HRTX) Soars 60% After positive results from Phase 3 MAGIC Study of SUSTOL Print E-mail
By David Fowler   
Friday, 29 May 2015 21:12
Heron Therapeutics Inc. (NASDAQ:HRTX) has confirmed robust top-line results from the recently completed Phase 3 MAGIC study.
Read more...
 
Biocept Inc. (NASDAQ:BIOC)’s Blood-based Liquid Biopsy for Non-small Cell Lung Carcinoma Print E-mail
By William Kent   
Thursday, 28 May 2015 19:23
Molecular diagnostics company Biocept Inc. (NASDAQ:BIOC), which is involved in developing and commercialising liquid biopsies for improving diagnosis as well as treatment of cancer will carry on building evidence of clinical utility of the liquid biopsy offerings and give an abstract at 2015 Annual American Society of Clinical Oncology Meeting in Chicago.
Read more...
 
IntelliPharmaCeutics Intl Inc (USA)(NASDAQ:IPCI): FDA Grants Fast Track Designation for Rexista Oxycodone XR Incorporating PODRAS(TM) Technology Print E-mail
By Josh Gee   
Wednesday, 27 May 2015 18:37
Pharmaceutical firm IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has confirmed that the United States Food and Drug Administration (“FDA”) has assessed the firm’s request for Fast Track designation of its abuse deterrent Rexista Oxycodone XR extended-release tablets development program that would have the Paradoxical OverDose Resistance Activating System.
Read more...
 
Janssen gets into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for combating Hepatitis C Virus Print E-mail
By Josh Gee   
Wednesday, 20 May 2015 13:59
Janssen Pharmaceuticals has confirmed entering into exclusive worldwide license as well as collaboration arrangement with Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for developing and commercializing Achillion's lead hepatitis C virus assets.
Read more...
 
Quiet biotech gains traction after cancer vaccine draws national media coverage ahead of upcoming ASCO meeting Print E-mail
By Josh Gee   
Wednesday, 20 May 2015 00:20
icon_bmrlogo Shares of TapImmune Inc. (otcqb:TPIV), a tiny publicly traded biotech, are breaking out as microcap investors are seeing the firm as holding the key to a major breakthrough.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 4 of 12

Newsletter